Felbatol is effective as:

• monotherapy and adjunctive therapy for partial-onset seizures and tonic-clonic seizures in adults 14 years of age and older
• adjunctive therapy for partial and generalized seizures, including the atonic seizures associated with Lennox-Gastaut syndrome, in children aged 2 to 14 years

Felbatol is recommended only for those patients whose epilepsy is so severe that a substantial risk of aplastic anemia or liver failure is considered acceptable in light of the potential benefits of its use. If these criteria are met, and the patient has been fully advised of the risk, Felbatol can be considered for use either alone or in combination with other seizure medicines.

Before deciding to prescribe Felbatol, read the information on Serious Side Effects on this site. Read the black box warning in the Package Insert to your patient and obtain any necessary signatures. The package insert includes a model patient consent form, but no special form is required.